forum health semaglutide Getting to the heart of GLP-1 Newer Weight-Loss Drugs Not Cost-effective

Hargraves, W

Novo Nordisk has added ileus to the Postmarketing Experience section of the Wegovy label under Gastrointestinal Disorders. In October 2025, Severe Gastrointestinal Adverse Reactions was added to the WARNING AND PRECAUTIONS section of the label

5 Keep unopened vials refrigerated until use

As with all unlicensed peptides, parenteral administration carries the usual risks of injection-site reaction and contamination if non-sterile material is used

The cost associated with including these GLP-1s on the health plan to reduce obesity actually did the opposite: it led to an increased claims liability for the employer and insurance companies

Its available now and helping thousands to achieve weight loss that was rarely possible with older medications